ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin-converting enzyme (ACE) inhibitor proven effective in improving survival following heart attacks.

17 May 2021

A look at how coronavirus disease (COVID-19) affects Parkinson's

Earlier, herpes simplex virus (HSV), influenza virus A, measles virus, cytomegalovirus (CMV), and mumps virus have all been associated with after-effects of the virus that includes Parkinson's disease (PD). This list may now include SARS-CoV-2.

14 May 2021

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

An interesting poster, just presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics 2021, reports an association between the use of certain heart medications and the risk of COVID-19.

27 Apr 2021

Researchers develop innovative profiling methods for SARS-CoV-2 infection

A team of researchers from various institutions in the USA used RNA-sequencing data and other methods to profile unique genes and other characteristics associated with SARS-CoV-2 in New York City (NYC).

17 Mar 2021

New guidelines aim to help reduce blood pressure for chronic kidney disease patients

A recommendation for more intensive blood pressure management from an influential global nonprofit that publishes clinical practice guidelines in kidney disease could, if followed, benefit nearly 25 million Americans, according to an analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health.

23 Feb 2021

Two common blood pressure drugs are not tied to increased risk of COVID-19

Research published in the peer-reviewed journal The Lancet Digital Health and co-led by a UCLA Fielding School of Public Health faculty member has found that two widely used types of blood pressure drugs are not tied to an increased risk of COVID-19 infection or complications.

18 Jan 2021

Patient with hypertension or cardiovascular diseases experienced critical disease progression with COVID-19

COVID-19 patients who also suffer from high blood pressure are more likely to fall severely ill with the disease, which also leaves them at greater risk of death.

11 Jan 2021

Stopping RAS inhibitors linked to risk of adverse outcomes in patients with chronic kidney disease

Small studies have suggested that a group of medications called RAS inhibitors may be harmful in persons with advanced chronic kidney disease, and physicians therefore often stop the treatment in such patients.

29 Dec 2020

Could the keto diet help prevent or mitigate severe COVID-19?

A new study published in the journal of Translational Medicine reports that the ketogenic diet (KD) may be useful in this area, with its track history of effectual reduction of fat mass, anti-inflammatory and immunomodulatory effects, and consequent improvement of cardiovascular health.

30 Nov 2020

Genetic mutation may accelerate heart function decline in DMD patients

A mutation in the gene that causes cystic fibrosis may accelerate heart function decline in those with Duchenne muscular dystrophy (DMD), a new study by UT Southwestern researchers suggests.

4 Nov 2020

Study finds sex differences among young individuals who suffer a heart attack

Women aged 50 or younger who suffer a heart attack are more likely than men to die over the following 11 years, according to a new study published today (Wednesday) in the European Heart Journal.

13 Oct 2020

Chronic illnesses promote active SARS-CoV-2 infection via suppressed mucosal immunity

A recent paper published in the preprint server medRxiv in September 2020 discusses the “clinically relevant variation in the expression of COVID-19-related genes”, which is associated with the host and environmental factors, as well as host genetic factors.

6 Oct 2020

Key China COVID-19 study produced results that influenced subsequent research on coronavirus

Early in the onset of the COVID-19 pandemic, a small study in China produced results that influenced subsequent research on the virus.

18 Sep 2020

Azithromycin use for treating COVID-19 may increase risk of cardiac events

Debates over whether hydroxychloroquine should be taken to help lessen the duration and impact of COVID-19 have revolved around the drug's reputation for causing cardiac events such as abnormal heart rhythms or beats and cardiac arrest.

16 Sep 2020

Computational models screen for coronaviruses likely to infect humans

The researchers from Rochester Institute of Technology and the Hauptmann-Woodward Medical Research Institute produced models of the receptor-binding domain (RBD) found on outbreak strains of betacoronaviruses and its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2).

14 Sep 2020

Mount Sinai hospitals win top quality achievement awards for stroke and cardiac care

Seven Mount Sinai Health System hospitals have received top quality achievement awards from the American Heart Association for ensuring that patients with stroke, heart failure, and severe heart attacks receive the most appropriate and safest treatment for the best possible outcomes.

1 Sep 2020

Common heart drugs are safe for patients hospitalized with COVID-19

Heart patients hospitalized with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial presented in a Hot Line session today at ESC Congress 2020.

1 Sep 2020

$Sacubitril/valsartan therapy may reduce hospitalization in heart patients with preserved ejection fraction$

Sacubitril/valsartan therapy may reduce hospitalization in heart patients with preserved ejection fraction

Sacubitril/valsartan reduces NT-proBNP, a biomarker predictive of long-term clinical outcomes in heart failure, but does not improve functional capacity compared to individualized background therapy in patients with heart failure with preserved ejection fraction

1 Sep 2020

SGLT2 inhibitors can slow CKD progression

850 million people worldwide are affected by chronic kidney disease (CKD) - a worrying figure, and one that continues to rise.

31 Aug 2020

Antihypertensive drugs are not linked to cancer, shows study

There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to the most extensive study conducted on the topic. The late breaking research is presented today at ESC Congress 2020.

31 Aug 2020

ACE Inhibitors News and Research

Further Reading

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

A look at how coronavirus disease (COVID-19) affects Parkinson's

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

Researchers develop innovative profiling methods for SARS-CoV-2 infection

New guidelines aim to help reduce blood pressure for chronic kidney disease patients

Two common blood pressure drugs are not tied to increased risk of COVID-19

Patient with hypertension or cardiovascular diseases experienced critical disease progression with COVID-19

Stopping RAS inhibitors linked to risk of adverse outcomes in patients with chronic kidney disease

Could the keto diet help prevent or mitigate severe COVID-19?

Genetic mutation may accelerate heart function decline in DMD patients

Study finds sex differences among young individuals who suffer a heart attack

Chronic illnesses promote active SARS-CoV-2 infection via suppressed mucosal immunity

Key China COVID-19 study produced results that influenced subsequent research on coronavirus

Azithromycin use for treating COVID-19 may increase risk of cardiac events

Computational models screen for coronaviruses likely to infect humans

Mount Sinai hospitals win top quality achievement awards for stroke and cardiac care

Common heart drugs are safe for patients hospitalized with COVID-19

Sacubitril/valsartan therapy may reduce hospitalization in heart patients with preserved ejection fraction

SGLT2 inhibitors can slow CKD progression

Antihypertensive drugs are not linked to cancer, shows study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News